美国临床试验市场规模、份额和趋势分析报告:按阶段(I、II、III、IV 期)、临床试验设计(介入试验、观察试验、扩大试验)、适应症、分部预测,2022- 2030年
市场调查报告书
商品编码
1170933

美国临床试验市场规模、份额和趋势分析报告:按阶段(I、II、III、IV 期)、临床试验设计(介入试验、观察试验、扩大试验)、适应症、分部预测,2022- 2030年

U.S. Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, II, III, IV), By Study Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, And Segment Forecasts, 2022 - 2030

出版日期: | 出版商: Grand View Research | 英文 204 Pages | 商品交期: 2-10个工作天内

价格

美国临床试验市场的增长和趋势

根据 Grand View Research, Inc. 的最新报告,美国临床试验市场预计到 2030 年将达到 363 亿美元。从 2022 年到 2030 年,该市场预计将以 5.4% 的复合年增长率增长。美国慢性病患病率上升和对临床试验的需求不断增长正在推动市场增长。

预计在未来八年内,被诊断患有癌症的人数将增加数倍。儘管肿瘤学领域的研究大大提高了生存率,但预计全球癌症患者的数量仍将增加。胰腺癌预后较差,据说生存期为1至3年。每天约有 13 人被诊断出患有胃肠道间质瘤。美国每年有 60,000 多例新病例被诊断出肾细胞癌,癌症发病率的增加增加了对多种癌症有效治疗的需求。预计美国的疾病流行将增加研发投资,促进行业增长。

COVID-19 大流行已经停止了新的研究项目,并改变了对其他疾病的资源分配。临床试验样本的供应链也因边境关闭而中断。所以市场动盪不安。然而,COVID-19 的反应正在推动市场上的新领域,这些领域正在改变临床试验的实施方式。分布式/虚拟临床试验就是这样一种技术。虚拟临床试验在当前的 COVID-19 情景中发挥着关键作用。由于虚拟访问和远程患者监控,参与者获得了选择和保证,以最大限度地降低风险。监控小工具、软件工具和手机让参与者可以在家中完成他们的实验。

美国临床试验市场报告要点

III 期在 2021 年以 53.6% 的销售份额占据市场主导地位。这些试验更为重要,因为它们涉及 300 至 3000 名参与者并且持续时间更长。因此最昂贵的阶段

2021年介入板块占比最大,46.0%

根据适应症,肿瘤科预计在分析期间的复合年增长率最高,为 5.7%。这种增长归因于癌症病例数量的增加。因此,大量资金用于肿瘤学临床试验。

目录

第一章 调查方法和范围

  • 市场细分和范围
    • 临床试验设计
    • 展示
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 初步调查详情
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 型号详情
    • 商品流向分析(模型一)
    • 量价分析(模型二)
  • 二级信息列表
  • 主要信息列表
  • 缩略语表
  • 目的

第二章执行摘要

  • 市场展望
  • 分部展望
  • 竞争考虑

3 美国临床试验市场:变量、趋势和范围

  • 市场系列展望
    • 母公司的市场前景
    • 辅助市场展望
  • 绘製渗透率和增长前景
  • 按 COVID-19 阶段划分的产品管道分析
    • 开发中的疗法:271
    • 开发中的疫苗:106
  • 临床试验的快速跟踪
    • FDA 倡议 - CTAP
      • 加速 COVID-19 治疗干预和疫苗研发
  • 合作临床试验
    • 参与协作临床试验
    • 疫苗的协同临床试验
  • 虚拟临床试验
    • 家庭保健服务:
  • COVID-19 大流行对临床试验活动的影响
    • 暂停临床试验:
    • 临床试验的障碍:
  • 市场动态
    • 市场驱动力分析
      • 在临床研究中采用新技术
      • 转向个性化医疗
      • 疾病变异和患病率增加
      • 加强生物医学研究合作
      • CRO市场的增长
    • 市场约束因素分析
      • 价格压力
    • 行业挑战
      • 临床试验成本上升
  • 美国临床试验市场分析工具
    • 波特五力分析
    • PESTEL 分析
    • 重大交易及战略联盟分析
      • 合作
      • 扩张
      • 合伙
      • 获得
      • 产品发布会
      • 合併
      • 合资企业

第四章美国临床试验市场:阶段分析

  • 美国临床试验:2021 年和 2030 年市场份额分析
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

5美国临床试验市场:临床试验设计的分段分析

  • 美国临床试验:2021 年和 2030 年市场份额分析
  • 干预试验
  • 观察测试
  • 扩展访问测试

6 美国临床试验市场:适应症细分分析

  • 美国临床试验:2021 年和 2030 年市场份额分析
  • 自身免疫/炎症
    • 类风湿关节炎
    • 多发性硬化症 (MS)
    • 骨关节炎
    • 肠易激综合症 (IBS)
    • 其他
  • 疼痛管理
    • 慢性疼痛
    • 急性疼痛
  • 肿瘤学
    • 血癌
    • 实体瘤
    • 其他
  • 中枢神经系统状况
    • 癫痫
    • 帕金森病 (PD)
    • 亨廷顿氏病
    • 中风
    • 创伤性脑损伤 (TBI)
    • 肌萎缩侧索硬化症 (ALS)
    • 肌肉再生
    • 其他
  • 糖尿病
  • 肥胖
  • 心血管
  • 其他适应症

7 项美国临床试验:适应症展望,通过临床试验设计,通过交叉分析

  • 自身免疫/炎症:美国临床试验市场,按临床试验设计,2018-2030(百万美元)
    • 干预试验
    • 观察测试
    • 扩展访问测试
  • 疼痛管理:美国临床试验市场,按临床试验设计,2018-2030 年(百万美元)
    • 干预试验
    • 观察测试
    • 扩展访问测试
  • 肿瘤学:美国临床试验市场,按临床试验设计,2018-2030 年(百万美元)
    • 干预试验
    • 观察测试
    • 扩展访问测试
  • CNS 状态:美国临床试验市场,按临床试验设计,2018-2030(百万美元)
    • 干预试验
    • 观察测试
    • 扩展访问测试
  • 糖尿病:美国临床试验市场,按试验设计,2018-2030 年(百万美元)
    • 干预试验
    • 观察测试
    • 扩展访问测试
  • 按临床试验设计划分的美国肥胖临床试验市场,2018-2030 年(百万美元)
    • 干预试验
    • 观察测试
    • 扩展访问测试
  • 心血管:美国临床试验市场,按临床试验设计,2018-2030(百万美元)
    • 干预试验
    • 观察测试
    • 扩展访问测试
  • 其他:美国临床试验市场,按临床试验设计,2018-2030(百万美元)
    • 干预试验
    • 观察测试
    • 扩展访问测试

第八章公司简介

  • 公司简介
    • IQVIA Holdings Inc.
      • 公司简介
      • 财务绩效
      • 服务基准
      • 战略举措
    • PAREXEL International Corporation
      • 公司简介
      • 服务基准
      • 战略举措
    • Thermo Fisher Scientific(Pharmaceutical Product Development)
      • 公司简介
      • 服务基准
      • 战略举措
    • Charles River Laboratory
      • 公司简介
      • 财务绩效
      • 服务基准
      • 战略举措
    • ICON plc
      • 公司简介
      • 财务绩效
      • 服务基准
      • 战略举措
    • LabCorp
      • 公司简介
      • 财务绩效
      • 服务基准
      • 战略举措
    • Syneos Health Inc.
      • 公司简介
      • 财务绩效
      • 服务基准
      • 战略举措
    • SGS SA
      • 公司简介
      • 财务绩效
      • 服务基准
      • 战略举措
    • Wuxi AppTec
      • 公司简介
      • 财务绩效
      • 服务基准
      • 战略举措
    • Eli Lilly and Company
      • 公司简介
      • 财务绩效
      • 服务基准
    • Novo Nordisk A/S
      • 公司简介
      • 财务绩效
      • 服务基准
    • Pfizer Inc.
      • 公司简介
      • 财务绩效
      • 服务基准
      • 战略举措
    • Covance Inc.
      • 公司简介
      • 财务绩效
      • 服务基准
Product Code: GVR-4-68039-580-4

U.S. Clinical Trials Market Growth & Trends:

The U.S. clinical trials market size is expected to reach USD 36.3 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to expand at a CAGR of 5.4% from 2022 to 2030. The increasing prevalence of chronic disease and growing demand for clinical trials in the U.S. is boosting the growth of the market.

The number of people diagnosed with cancer is expected to increase multi-fold in the coming eight years. Although survivors have increased considerably owing to research in the oncology field, the number of cancer patients is expected to increase across the world. Pancreatic cancer has a poor prognosis with a survival of only 1 to 3 years. Approximately 13 people are diagnosed with GI stromal tumors each day. More than 60, 000 new cases of renal cell carcinoma are diagnosed every year in the U.S. Hence, representing an increasing prevalence of cancer and the need for effective treatments against various types of cancer. Investment in R&D is expected to grow owing to the disease prevalence across the U.S. thereby boosting the industry's growth.

The COVID-19 pandemic has halted new research projects and reallocated resources for other diseases. The supply chain for clinical trial samples has also been interrupted as a result of blocked borders. Hence, this market is disrupted. However, the COVID-19 response has resulted in new developments on the market that have transformed the conduct of clinical trials. Decentralized/virtual clinical trials are one such technique. Virtual trials have a very important role in the current COVID-19 scenario. As a result of the virtual visit and remote patient monitoring, participants have a choice and peace of mind to minimize risks. Monitoring gadgets, software tools, and mobile phones enable participants to complete the experiment from their homes.

U.S. Clinical Trials Market Report Highlights:

  • Phase III dominated the market with a revenue share of 53.6% in 2021. These trials are more crucial as they involve 300 to 3000 participants and have a longer period of time. Thus, it is the most expensive phase
  • The interventional segment accounted for the largest share of 46.0% in 2021
  • Based on indication, the oncology segment is anticipated to exhibit the highest CAGR of 5.7% over the analysis timeframe. This growth is due to the growing number of cases of cancer. Thus, a large amount of expenditure is spent on oncology clinical trials

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Phase
    • 1.1.2 Study Design
    • 1.1.3 Indication
    • 1.1.4 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
    • 1.6.2 Volume Price Analysis (Model 2)
  • 1.7 List Of Secondary Sources
  • 1.8 List Of Primary Sources
  • 1.9 List Of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective - 1:
    • 1.10.2 Objective - 2:
    • 1.10.3 Objective - 3:
    • 1.10.4 Objective - 4:

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Insights

Chapter 3 U.S. Clinical Trials Market: Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
    • 3.1.2 Ancillary market outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Product Pipeline Analysis, by Stage for COVID-19
    • 3.3.1 Therapeutics in development: 271
    • 3.3.2 Vaccines in development: 106
  • 3.4 Fast track of clinical trials
    • 3.4.1 FDA initiative- CTAP
      • 3.4.1.1 Accelerating COVID-19 Therapeutic Interventions and Vaccines
  • 3.5 Solidarity clinical trial
    • 3.5.1 Participation in solidarity trials
    • 3.5.2 Solidarity clinical trial for vaccines
  • 3.6 Virtual clinical trials
    • 3.6.1 In-home clinical services:
  • 3.7 COVID-19 pandemic impact on clinical trial activity
    • 3.7.1 Disrupted clinical trials:
    • 3.7.2 Obstacles in clinical trials:
  • 3.8 Market Dynamics
    • 3.8.1 Market Driver Analysis
      • 3.8.1.1 Adoption of new technology in clinical research
      • 3.8.1.2 Shift towards personalized medicine
      • 3.8.1.3 Growing disease variation and prevalence
      • 3.8.1.4 Increasing collaboration in biomedical research
      • 3.8.1.5 Growth in CRO market
    • 3.8.2 Market Restraint Analysis
      • 3.8.2.1 Pricing pressure
    • 3.8.3 Industry Challenges
      • 3.8.3.1 Rising cost of clinical trial
  • 3.9 U.S. Clinical Trials Market Analysis Tools
    • 3.9.1 Porter's Five Forces Analysis
    • 3.9.2 PESTEL Analysis
    • 3.9.3 Major Deals & Strategic Alliances Analysis
      • 3.9.3.1 Collaboration
      • 3.9.3.2 Expansion
      • 3.9.3.3 Partnership
      • 3.9.3.4 Acquisition
      • 3.9.3.5 Product launch
      • 3.9.3.6 Merger
      • 3.9.3.7 Joint venture

Chapter 4 U.S. Clinical Trials Market: Phase Segment Analysis

  • 4.1 U.S. Clinical Trials: Market Share Analysis, 2021 & 2030
  • 4.2 Phase I
    • 4.2.1 Phase I market, 2018 - 2030 (USD Million)
  • 4.3 Phase II
    • 4.3.1 Phase II market, 2018 - 2030 (USD Million)
  • 4.4 Phase III
    • 4.4.1 Phase III market, 2018 - 2030 (USD Million)
  • 4.5 Phase IV
    • 4.5.1 Phase IV market, 2018 - 2030 (USD Million)

Chapter 5 U.S. Clinical Trials Market: Study Design Segment Analysis

  • 5.1 U.S. Clinical Trials: Market Share Analysis, 2021 & 2030
  • 5.2 Interventional Studies
    • 5.2.1 Interventional market, 2018 - 2030 (USD Million)
  • 5.3 Observational Studies
    • 5.3.1 Observational studies market, 2018 - 2030 (USD Million)
  • 5.4 Expanded Access Studies
    • 5.4.1 Expanded access studies market, 2018 - 2030 (USD Million)

Chapter 6 U.S. Clinical Trials Market: Indication Segment Analysis

  • 6.1 U.S. Clinical Trials: Market Share Analysis, 2021 & 2030
  • 6.2 Autoimmune/Inflammation
    • 6.2.1 Autoimmune/inflammation market, 2018 - 2030 (USD Million)
    • 6.2.2 Rheumatoid Arthritis
      • 6.2.2.1 Rheumatoid arthritis market, 2018 - 2030 (USD Million)
    • 6.2.3 Multiple Sclerosis (MS)
      • 6.2.3.1 Multiple sclerosis market, 2018 - 2030 (USD Million)
    • 6.2.4 Osteoarthritis
      • 6.2.4.1 Osteoarthritis market, 2018 - 2030 (USD Million)
    • 6.2.5 Irritable Bowel Syndrome (IBS)
      • 6.2.5.1 Irritable Bowel Syndrome (IBS) market, 2018 - 2030 (USD Million)
    • 6.2.6 Others
      • 6.2.6.1 Others market, 2018 - 2030 (USD Million)
  • 6.3 Pain Management
    • 6.3.1 Pain management market, 2018 - 2030 (USD Million)
    • 6.3.2 Chronic pain
      • 6.3.2.1 Chronic pain market, 2018 - 2030 (USD Million)
    • 6.3.3 Acute pain
      • 6.3.3.1 Acute pain market, 2018 - 2030 (USD Million)
  • 6.4 Oncology
    • 6.4.1 Oncology market, 2018 - 2030 (USD Million)
    • 6.4.2 Blood cancer
      • 6.4.2.1 Blood cancer market, 2018 - 2030 (USD Million)
    • 6.4.3 Solid tumors
      • 6.4.3.1 Solid tumors market, 2018 - 2030 (USD Million)
    • 6.4.4 Others
      • 6.4.4.1 Others market, 2018 - 2030 (USD Million)
  • 6.5 CNS Conditions
    • 6.5.1 CNS conditions market, 2018 - 2030 (USD Million)
    • 6.5.2 Epilepsy
      • 6.5.2.1 Epilepsy market, 2018 - 2030 (USD Million)
    • 6.5.3 Parkinson's disease (PD)
      • 6.5.3.1 Parkinson's disease (PD) market, 2018 - 2030 (USD Million)
    • 6.5.4 Huntington's disease
      • 6.5.4.1 Huntington's disease market, 2018 - 2030 (USD Million)
    • 6.5.5 Stroke
      • 6.5.5.1 Stroke market, 2018 - 2030 (USD Million)
    • 6.5.6 Traumatic Brain Injury (TBI)
      • 6.5.6.1 Traumatic Brain Injury (TBI) market, 2018 - 2030 (USD Million)
    • 6.5.7 Amyotrophic Lateral Sclerosis (ALS)
      • 6.5.7.1 Amyotrophic Lateral Sclerosis (ALS) market, 2018 - 2030 (USD Million)
    • 6.5.8 Muscle Regeneration
      • 6.5.8.1 Muscle Regeneration market, 2018 - 2030 (USD Million)
    • 6.5.9 Others
      • 6.5.9.1 Others market, 2018 - 2030 (USD Million)
  • 6.6 Diabetes
    • 6.6.1 Diabetes market, 2018 - 2030 (USD Million)
  • 6.7 Obesity
    • 6.7.1 Obesity market, 2018 - 2030 (USD Million)
  • 6.8 Cardiovascular
    • 6.8.1 Cardiovascular market, 2018 - 2030 (USD Million)
  • 6.9 Other Indications
    • 6.9.1 Other indications market, 2018 - 2030 (USD Million)

Chapter 7 U.S. Clinical Trials Indication Outlook, by Study Design, Criss-Cross Analysis

  • 7.1 U.S. autoimmune/inflammation clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.1.1 Interventional studies
      • 7.1.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.1.2 Observational Studies
      • 7.1.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.1.3 Expanded access
      • 7.1.3.1 Expanded access market, 2018 - 2030 (USD Million)
  • 7.2 U.S. pain management clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.2.1 Interventional studies
      • 7.2.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.2.2 Observational studies
      • 7.2.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.2.3 Expanded access
      • 7.2.3.1 Expanded access market, 2018 - 2030 (USD Million)
  • 7.3 U.S. Oncology clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.3.1 Interventional studies
      • 7.3.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.3.2 Observational studies
      • 7.3.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.3.3 Expanded access
      • 7.3.3.1 Expanded access market, 2018 - 2030 (USD Million)
  • 7.4 U.S. CNS condition clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.4.1 Interventional studies
      • 7.4.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.4.2 Observational studies
      • 7.4.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.4.3 Expanded access
      • 7.4.3.1 Expanded access market, 2018 - 2030 (USD Million)
  • 7.5 U.S. diabetes clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.5.1 Interventional studies
      • 7.5.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.5.2 Observational studies
      • 7.5.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.5.3 Expanded access
      • 7.5.3.1 Expanded access market, 2018 - 2030 (USD Million)
  • 7.6 U.S. obesity clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.6.1 Interventional studies
      • 7.6.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.6.2 Observational studies
      • 7.6.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.6.3 Expanded access
      • 7.6.3.1 Expanded access market, 2018 - 2030 (USD Million)
  • 7.7 U.S. cardiovascular clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.7.1 Interventional studies
      • 7.7.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.7.2 Observational Studies
      • 7.7.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.7.3 Expanded access
      • 7.7.3.1 Expanded access market, 2018 - 2030 (USD Million)
  • 7.8 U.S. others clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.8.1 Interventional studies
      • 7.8.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.8.2 Observational Studies
      • 7.8.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.8.3 Expanded access
      • 7.8.3.1 Expanded access market, 2018 - 2030 (USD Million)

Chapter 8 Company Profiles

  • 8.1 Company Profiles
    • 8.1.1 IQVIA Holdings Inc.
      • 8.1.1.1 Company overview
      • 8.1.1.2 Financial performance
      • 8.1.1.3 Service benchmarking
      • 8.1.1.4 Strategic initiatives
    • 8.1.2 PAREXEL International Corporation
      • 8.1.2.1 Company overview
      • 8.1.2.2 Service benchmarking
      • 8.1.2.3 Strategic initiatives
    • 8.1.3 Thermo Fisher Scientific (Pharmaceutical Product Development)
      • 8.1.3.1 Company overview
      • 8.1.3.2 Service benchmarking
      • 8.1.3.3 Strategic initiatives
    • 8.1.4 Charles River Laboratory
      • 8.1.4.1 Company overview
      • 8.1.4.2 Financial performance
      • 8.1.4.3 Service benchmarking
      • 8.1.4.4 Strategic initiatives
    • 8.1.5 ICON plc
      • 8.1.5.1 Company overview
      • 8.1.5.2 Financial performance
      • 8.1.5.3 Service benchmarking
      • 8.1.5.4 Strategic initiatives
    • 8.1.6 LabCorp
      • 8.1.6.1 Company overview
      • 8.1.6.2 Financial performance
      • 8.1.6.3 Service benchmarking
      • 8.1.6.4 Strategic initiatives
    • 8.1.7 Syneos Health Inc.
      • 8.1.7.1 Company overview
      • 8.1.7.2 Financial performance
      • 8.1.7.3 Service benchmarking
      • 8.1.7.4 Strategic initiatives
    • 8.1.8 SGS SA
      • 8.1.8.1 Company overview
      • 8.1.8.2 Financial performance
      • 8.1.8.3 Service benchmarking
      • 8.1.8.4 Strategic initiatives
    • 8.1.9 Wuxi AppTec
      • 8.1.9.1 Company overview
      • 8.1.9.2 Financial performance
      • 8.1.9.3 Service benchmarking
      • 8.1.9.4 Strategic initiatives
    • 8.1.10 Eli Lilly and Company
      • 8.1.10.1 Company overview
      • 8.1.10.2 Financial performance
      • 8.1.10.3 Service benchmarking
    • 8.1.11 Novo Nordisk A/S
      • 8.1.11.1 Company overview
      • 8.1.11.2 Financial performance
      • 8.1.11.3 Service benchmarking
    • 8.1.12 Pfizer Inc.
      • 8.1.12.1 Company overview
      • 8.1.12.2 Financial performance
      • 8.1.12.3 Service benchmarking
      • 8.1.12.4 Strategic initiatives
    • 8.1.13 Covance Inc.
      • 8.1.13.1 Company overview
      • 8.1.13.2 Financial performance
      • 8.1.13.3 Service benchmarking

List of Tables

  • Table 1 U.S. clinical trials market, by phase, 2018 - 2030 (USD Million)
  • Table 2 U.S. clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 3 U.S. clinical trials market, by indication, 2018 - 2030 (USD Million)
  • Table 4 U.S. autoimmune/inflammation clinical trials market, by indication, 2018 - 2030 (USD Million)
  • Table 5 U.S. pain management clinical trials market, by indication, 2018 - 2030 (USD Million)
  • Table 6 U.S. oncology clinical trials market, by indication, 2018 - 2030 (USD Million)
  • Table 7 U.S. CNS conditions clinical trials market, by indication, 2018 - 2030 (USD Million)
  • Table 8 U.S. autoimmune/inflammation clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 9 U.S. pain management clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 10 U.S. oncology clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 11 U.S. CNS condition clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 12 U.S. diabetes clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 13 U.S. obesity clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 14 U.S. cardiovascular clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 15 U.S. others clinical trials market, by study design, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Volume price analysis
  • Fig. 9 U.S. Clinical trials market snapshot (2021)
  • Fig. 10 U.S. clinical trials market segmentation
  • Fig. 11 U.S. clinical trials market: Strategy framework
  • Fig. 12 Parent market outlook
  • Fig. 13 Related/ancillary market outlook
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Virtual clinical trials
  • Fig. 16 Companies with affected trials, by size
  • Fig. 17 Affected trials, by study phase
  • Fig. 18 Market driver relevance analysis (Current & future impact)
  • Fig. 19 Market restraint relevance analysis (Current & future impact)
  • Fig. 20 Porter's five forces analysis
  • Fig. 21 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 22 U.S. clinical trials market phase outlook: Segment dashboard
  • Fig. 23 U.S. clinical trials market: Phase movement analysis
  • Fig. 24 Phase I market, 2018 - 2030 (USD Million)
  • Fig. 25 Phase II market, 2018 - 2030 (USD Million)
  • Fig. 26 Phase III market, 2018 - 2030 (USD Million)
  • Fig. 27 Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. clinical trials market study design outlook: Segment dashboard
  • Fig. 29 U.S. clinical trials market: Study design movement analysis
  • Fig. 30 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 31 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 32 Expanded access studies market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. clinical trials market indication outlook: Segment dashboard
  • Fig. 34 U.S. clinical trials market: Indication movement analysis
  • Fig. 35 Autoimmune/inflammation market, 2018 - 2030 (USD Million)
  • Fig. 36 Rheumatoid arthritis clinical trial by phase (%)
  • Fig. 37 Rheumatoid arthritis market, 2018 - 2030 (USD Million)
  • Fig. 38 Multiple sclerosis clinical trial by phase (%)
  • Fig. 39 Multiple sclerosis market, 2018 - 2030 (USD Million)
  • Fig. 40 Osteoarthritis clinical trials by phase (%)
  • Fig. 41 Osteoarthritis market, 2018 - 2030 (USD Million)
  • Fig. 42 Irritable bowel syndrome clinical trials by phase (%)
  • Fig. 43 Irritable Bowel Syndrome (IBS) market, 2018 - 2030 (USD Million)
  • Fig. 44 Others market, 2018 - 2030 (USD Million)
  • Fig. 45 Pain management market, 2018 - 2030 (USD Million)
  • Fig. 46 Chronic pain clinical trial by phase (%)
  • Fig. 47 Chronic pain market, 2018 - 2030 (USD Million)
  • Fig. 48 Acute pain clinical trial by phase (%)
  • Fig. 49 Acute pain market, 2018 - 2030 (USD Million)
  • Fig. 50 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 51 Blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 52 Solid tumors market, 2018 - 2030 (USD Million)
  • Fig. 53 Others market, 2018 - 2030 (USD Million)
  • Fig. 54 CNS conditions market, 2018 - 2030 (USD Million)
  • Fig. 55 Epilepsy market, 2018 - 2030 (USD Million)
  • Fig. 56 Parkinson's disease (PD) market, 2018 - 2030 (USD Million)
  • Fig. 57 Huntington's disease market, 2018 - 2030 (USD Million)
  • Fig. 58 Stroke market, 2018 - 2030 (USD Million)
  • Fig. 59 Traumatic Brain Injury (TBI) market, 2018 - 2030 (USD Million)
  • Fig. 60 Amyotrophic lateral sclerosis (ALS) market, 2018 - 2030 (USD Million)
  • Fig. 61 Muscle regeneration market, 2018 - 2030 (USD Million
  • Fig. 62 Others market, 2018 - 2030 (USD Million)
  • Fig. 63 Diabetes market, 2018 - 2030 (USD Million)
  • Fig. 64 Obesity clinical trial by phase (%)
  • Fig. 65 Obesity market, 2018 - 2030 (USD Million)
  • Fig. 66 Cardiovascular market, 2018 - 2030 (USD Million)
  • Fig. 67 Others indications market, 2018 - 2030 (USD Million)
  • Fig. 68 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 69 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 70 Expanded access market, 2018 - 2030 (USD Million)
  • Fig. 71 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 72 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 73 Expanded access market, 2018 - 2030 (USD Million)
  • Fig. 74 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 75 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 76 Expanded access market, 2018 - 2030 (USD Million)
  • Fig. 77 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 78 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 79 Expanded access market, 2018 - 2030 (USD Million)
  • Fig. 80 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 81 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 82 Expanded access market, 2018 - 2030 (USD Million)
  • Fig. 83 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 84 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 85 Expanded access market, 2018 - 2030 (USD Million)
  • Fig. 86 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 87 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 88 Expanded access market, 2018 - 2030 (USD Million)
  • Fig. 89 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 90 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 91 Expanded access market, 2018 - 2030 (USD Million)